Clinical trials: completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC
- Lead sponsor (exact) European Organisation for Research and Treatment of Cancer - EORTC
- Status Completed
NSCLC
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a new standard for testing tumor progression compared with conventional radiological procedure in EGFR mutant advanced NSCLC patients.
- Trial name
- APPLE (NCT02856893)
- Testing
- Osimertinib, Gefitinib
- Where
- 23 sites in Belgium, France and 4 more
- Volunteers
- 156 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Follow-up in Early and Locally Advanced Breast Cancer Patients
A cross-sectional follow-up study of Early and Locally Advanced Breast Cancer patients after primary treatment.
- Trial name
- NCT03859453
- Where
- 28 sites in Belgium, France and 8 more
- Volunteers
- 830 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer
RATIONALE: Adjuvant therapy given after surgery for early breast cancer may cause infertility. Assessing young women's attitudes and feelings about the risk of infertility may help improve the ability to plan effective treatment.
- Conditions
- Breast Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues
- Trial name
- NCT00062400
- Testing
- psychosocial assessment and care
- Where
- 27 sites in Belgium, Chile and 13 more
- Volunteers
- 385 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease.
- Conditions
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- Trial name
- SPECTAlung (NCT02214134)
- Testing
- Tumour markers testing
- Where
- 18 sites in Belgium, France and 7 more
- Volunteers
- 539 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Uterine Sarcoma
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread.
- Trial name
- NCT01979393
- Testing
- Cabozantinib
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 58 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard…
- Conditions
- Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
- Trial name
- INNOVATION (NCT02205047)
- Testing
- Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab
- Where
- 48 sites in Belgium, Estonia and 11 more
- Volunteers
- 172 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent High Grade Meningioma
Trabectedin for Recurrent Grade II/III Meningioma
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
- Trial name
- NCT02234050
- Testing
- Trabectedin, Local standard of care
- Where
- 47 sites in Austria, Belgium and 8 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Newly Diagnosed Glioblastoma
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal.
- Trial name
- MIRAGE (NCT03345095)
- Testing
- Marizomib, Temozolomide, radiotherapy
- Where
- 82 sites in United States, Austria and 10 more
- Volunteers
- 749 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Salivary Gland Cancer
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers.
- Trial name
- NCT01969578
- Testing
- bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- LAPATAM (NCT00424164)
- Testing
- lapatinib ditosylate, tamoxifen citrate, pharmacological study
- Where
- France
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00036868
- Testing
- trastuzumab, CMF regimen, cyclophosphamide
- Where
- 13 sites in Belgium, Denmark and 7 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years.
- Trial name
- NCT03770468
- Testing
- Blood drawl
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 599 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Colon Cancer Liver Metastasis
Diffusion-Weighted MRI for Liver Metastasis
The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination with other imaging modalities (multiparametric MRI and CT Scan) in determining the true status of disappearing liver metastasis (DLM)…
- Conditions
- Colorectal Cancer, Colon Cancer Liver Metastasis, Malignant Neoplasm of Rectum Metastatic to Liver
- Trial name
- DREAM (NCT02781935)
- Testing
- DW-MRI
- Where
- 21 sites in United States, Austria and 3 more
- Volunteers
- 233 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Fallopian Tube Cancer, Ovarian Cancer
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01402271
- Testing
- carboplatin, paclitaxel, pazopanib hydrochloride
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small Cell Lung Cancer (SCLC)
Pembrolizumab in Untreated Extensive SCLC
This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.
- Trial name
- REACTION (NCT02580994)
- Testing
- Pembrolizumab, cis/carboplatin and etoposide
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 125 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Fungal Infection, Leukemia
Empirical Versus Preemptive Antifungal Therapy
RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their cancer.
- Conditions
- Fungal Infection, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT01288378
- Testing
- caspofungin acetate
- Where
- 16 sites in Belgium, Czechia and 4 more
- Volunteers
- 556 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Biliary Tract Cancer, Metastatic Cancer
Pembrolizumab in Biliary Tract Cancer
This is a single-arm, multi-centre, phase II study in biliary tract cancer (BTC) patients. The main objective is to detect an increase in progression-free survival rate at 6 months (according to RECIST version 1.1) from 60% in…
- Conditions
- Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer, Gallbladder Cancer
- Trial name
- NCT03260712
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 7 sites in Germany, Spain and 1 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC